Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:

Rheumatoid Arthritis Clinical Trial

Official title:

Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02342977
• Other study ID #: 1408905316
• Status: Withdrawn
• Phase: Phase 2
• First received: December 18, 2014
• Last updated: August 25, 2016
• Start date: November 2014
• Est. completion date: August 2016

Study information

• Verified date: August 2016
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine how effect lacosamide is in reducing the amount of pain medication needed following a total hip arthroplasty. The study team hypothesizes that a single dose of lacosamide will reduce the amount of pain medication required after surgery. The study team plans to evaluate the amount of pain medication needed and quality of pain control during a subject's hospital stay and at their three month follow-up visit following their surgery.

Description:

All patients who agree to participate in this study will receive the same surgical and anesthetic techniques that are provided to all our patients undergoing this procedure at this institution. Post-operative treatment and therapy and follow-up will also be the same as any of our patients undergoing this procedure at this institution.

The only difference would be that patients would be randomized (determined by chance, like a flip of a coin) to either receive a single dose of lacosamide (100 mg by mouth) or placebo (sugar pill by mouth) before the surgical procedure. This would be the only experimental part of this study.

In addition, specific information will be collected throughout the patients care until discharged from the orthopedic clinic (approximately 3 months after the procedure). The collected information will include subject's age, race and ethnicity, sex, height, weight, American Society of Anesthesiologist physical status, total amount of opioid (pain medication) use, pain scores, nausea and vomiting, time spent in the post anesthesia care unit (time to discharge readiness), and discharge from the hospital. The patient's pain score and opioid use will be assessed during their follow-up at approximately 3 months (Note: all of the specific information collected is normally gathered or documented in our surgical patients' record). In addition, participants may withdraw from the study at any time.

The main goal of this study is to determine if lacosamide can reduce the amount of opioids required in patient's undergoing a total hip arthroplasty. Lacosamide is a FDA approved medication for the treatment of partial-onset seizures and is a man-made amino acid (usually are used as the building blocks from which proteins are made in the body) which block special proteins inby a change in the electricity that a cell may feel (voltage-gated sodium channel). Lacosamide is a new antiepileptic drug apparently lacking any major pharmacokinetic interactions (how the body affects a specific drug after administration, as well as the chemical changes of the substance in the body, and the effects and routes of excretion of the metabolites of the drug).

Lacosamide, carbamazepine and oxcarbazepine are known to block special proteins in the covering of cells which allow sodium into the cells when they are turned on by a change in the electricity that a cell may feel (voltage-gated sodium channel, NaV1.7). Lacosamide was chosen over carbamazepine and oxcarbazepine because it causes fewer side effects. Currently, lacosamide is being tested in patients with painful diabetic nerve pain. Further trials to identify lacosamide's potential in pain control and for other indications have been started.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients will be eligible for participation if they are 18-70 years of age.

• Patients who have an American Society of Anesthesiologists physical status I-III.

• Patients who are scheduled for primary total hip arthroplasty.

• Any patients who are willing to comply with study requirements and agrees to be in the study.

Exclusion Criteria:

• A patient's refusal to participate.

• Inability to give consent.

• Any patients on a scheduled opioid regimen for pain greater than 3 months.

• Bleeding diathesis.

• Hypersensitivity to lacosamide or any component of the formulation (some formulation contains phenylalanine) and/or any drug allergies to any medications used in this study.

• Second- or third-degree atrioventricular (AV) block, sick sinus syndrome without pacemaker, sodium channelopathies (e.g., Brugada syndrome), myocardial ischemia, heart failure, and structural heart disease.

• Severe hepatic and or renal impairment.

• Pregnant or can become pregnant.

• Breast-Feeding.

• Have any suicidal thoughts, depression, or behavioral changes.

• Taking any antiepileptic medications.

• Any known seizure disorder (e.g. Lennox-Gastaut syndrome).

• Currently prescribed:

Carbamazepine Strong inhibitors of cytochrome P450-2C9 (Capecitabine; Delavirdine; floxuridine; Fluorouracil (Systemic); Gemfibrozil; Nicardipine; Sitaxentan; Sulfadiazine; Sulfissoxazole; Tegafur; Tolbutamide) Strong inhibitors of cytochrome P450-3A4 (Atazanavir; Boceprevir; Chloramphenicol; Clarithromycin; Cobicistat; Conivaptan; Darunavir; Delavirdine; Fosamprenavir; Indinavir; Itraconazole; Ketoconazole (Systemic); Lopinavir; Nefazodone; Nelfinavir; Nicardipine; Posaconazole; Ritonavir; Saquinavir; Telaprevir; Telithromycin; Voriconazole) Delavirdine Fosphenytoin Nicardipin Phenobarbital Phenytoin Ethinylestradiol

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis, Rheumatoid
• Avascular Necrosis
• Necrosis
• Osteoarthritis
• Rheumatoid Arthritis

Intervention

Drug:
• Placebo
Patients will randomly receive placebo
• Lacosamide
Patients will randomly receive lacosamide

Locations

Country	Name	City	State
United States	Richard L. Roudebush Veterans Affairs Medical Center	Indianapolis	Indiana

Sponsors (2)

Lead Sponsor	Collaborator
Indiana University School of Medicine	VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Opioid use in Post anesthesia care unit	Post operative opioid use.	30 minutes to 2 hours after surgery	No
Secondary	Pain scores	Post operative pain scores	Post operative Day #0 through hospital discharge (4 day average)	No
Secondary	Nausea and Vomiting	Post operative nausea and vomiting	Post operative Day #0 through hospital discharge (4 day average)	No
Secondary	Total opioid use	Total post operative opioid use	Post operative Day #0 through hospital discharge (4 day average)	No
Secondary	Time to PACU discharge readiness	Post operative discharge readiness	30 minutes to 2 hours after surgery	No
Secondary	Pain scores and opioid use at 3 month discharge	Development of chronic pain	At 3 month surgery follow up	No
Secondary	Time to hospital discharge	Hospital discharge	Post operative Day #0 through hospital discharge ( 4 day average )	No
Secondary	Possible side effects from Lacosamide	Possible side effects ( dizziness, headaches, visual changes, and nausea )	Post operative Day #0 through hospital discharge (4 day average)	Yes